Split History
ETFs Holding KALV »    KALV Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
KalVista Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. Co.'s first product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). Co. has a portfolio of oral plasma kallikrein inhibitors and multiple drug candidates in Phase 1 clinical trials for HAE in order to create oral therapies. In the case of DME, Co. is developing a plasma kallikrein inhibitor which is administered directly into the eye and anticipate ultimately developing orally delivered drugs. According to our KALV split history records, KalVista Pharmaceuticals has had 1 split.
KALV split history picture
KalVista Pharmaceuticals (KALV) has 1 split in our KALV split history database. The split for KALV took place on November 22, 2016. This was a 1 for 14 reverse split, meaning for each 14 shares of KALV owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 71.4285714285714 share position following the split.

When a company such as KalVista Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share. Looking at the KALV split history from start to finish, an original position size of 1000 shares would have turned into 71.4285714285714 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into KalVista Pharmaceuticals shares, starting with a $10,000 purchase of KALV, presented on a split-history-adjusted basis factoring in the complete KALV split history. KALV split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 04/09/2015
End date: 06/21/2019
Start price/share: $77.84
End price/share: $21.52
Dividends collected/share: $0.00
Total return: -72.35%
Average Annual Total Return: -26.35%
Starting investment: $10,000.00
Ending investment: $2,765.42
Years: 4.20
Date Ratio
11/22/20161 for 14
KALV is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

KBIO Split History
KIDS Split History
KOOL Split History
LCAV Split History
LCI Split History
LH Split History
LIFE Split History
LJPC Split History
LLY Split History
LPTN Split History

Also explore: KALV shares outstanding history

Xenetic Biosciences, Inc. (XBIO)
Yuma Energy, Inc. (YUMA)
Avinger, Inc. (AVGR)
Sonoma Pharmaceuticals, Inc. (SOMA)
Hudson Global, Inc. (HSON)
Jaguar Health, Inc. (JAGX)
Cesca Therapeutics Inc. (KOOL)
Northern Technologies International Corporation (NTIC)
Digirad Corporation (DRAD)
Hemispherx Biopharma, Inc. (HEB)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

KALV Insider Buying

KALV Split History | www.SplitHistory.com | Copyright © 2013 - 2019, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.